AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. (Withdrawn) A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:

950	
951	O N N N N N N N N N N N N N N N N N N N
952	O N N N
953	
954	OHRU NO
955	CHRU O N N N N N N N N N N N N N N N N N N
956	OHRAL N-H
957	0-N N-N

958	OHRAL PF
959	0-N N-N N
960	OHOU.
961	CHIPAL OF THE PARTY OF THE PART
962	CHIRAL F

963	chiral (+)
964	O-HPAL
965	OHRAL N
966	CHEAT N
967	OHRAL N. H.
968	N-N N-N N

969 a o n n n n n n	
970	
971	
972	
973	
974 chiral (+)	
975	
chiral (+)	

Docket No.: 15652-14300-US

4

976	OFFAL O
977	CHRUL CON N N N N N N N N N N N N N N N N N N
978	chiral (-)
979	chiral (+)
980	CHRAL OLD IN THE PROPERTY OF T

981	OHRU.
982	
983	. Alga
984	
985	
986	


Docket No.: 15652-14300-US

987	
988	N N N N N N N N N N N N N N N N N N N
989	
990	
991	N N N N N N N N N N N N N N N N N N N
992	N N N N N N N N N N N N N N N N N N N
993	

994	
995	
996	
997	
998	
999	
1000	
1001	0-N N-N

Docket No.: 15652-14300-US

1002	0-N N N N N N N N N N N N N N N N N N N
1003	0-N N-N
1004	CHRIA C



- (Withdrawn) A pharmaceutical formulation comprising as an active ingredient a
 therapeutically effective amount of a compound according to claim 1 in association with one or
 more pharmaceutically acceptable diluents, excipients and/or inert carriers.
- (Withdrawn) The pharmaceutical formulation according to claim 2, for use in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
- (Withdrawn) A compound according to claim 1 for use in therapy.
- (Withdrawn) The compound according to claim 1, for use in prevention and/or treatment of mGluR5 receptor-mediated disorders.
- (Withdrawn) The compound according to claim 5, wherein the disorder is a neurological disorder.
- (Withdrawn) The compound according to claim 5, wherein the disorder is a psychiatric disorder

 (Withdrawn) The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders.

- (Withdrawn) The compound according to claim 5, wherein the disorder is a gastrointestinal disorder.
- 10. (Withdrawn) The compound according to claim 5, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.
- (Withdrawn Currently Amended) <u>A method of manufacturing The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention and/or treatment of mGluR5 receptor-mediated disorders comprising a compound according to claim 1.
 </u>
- 12. (Currently Amended) A method of prevention and/or-treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention and/or treatment a therapeutically effective amount of a compound, aecording to elaim 1 or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds set forth in the following table:

943	CI N N N
944	O N N N N
945	CI N N N N N N N N N N N N N N N N N N N
946	
947	G

948	O N N N N N N N N N N N N N N N N N N N
949	
<u>950</u>	
<u>951</u>	
<u>952</u>	
<u>953</u>	

<u>954</u>	OHRIL OHRIL NO
<u>955</u>	OHRAL N-NNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN
<u>956</u>	CHRAL N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-
<u>957</u>	0-N N N N N N N N N N N N N N N N N N N
<u>958</u>	CHRAL
<u>959</u>	O-N N-N N
960	CHRAL ON N N N

<u>961</u>	CHEAL ON N
962	CHIRAL F
963	chiral (+)
964	OHOL N
965	OHPAL ON NOTE OF THE PARTY OF T

966	O SEOF
<u>967</u>	CHEOT
968	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
969	0-N N-N
970	
<u>971</u>	O-N N-N
<u>972</u>	


973	O-N N-N N
974	chiral (+)
975	chiral (+)
<u>976</u>	OHRAL ON N N N N N N N N N N N N N N N N N N
<u>977</u>	CHRUL CONN N N N N N N N N N N N N N N N N N N


978	chiral (-)
979	
	chiral (+)
980	CHRAL CHARLES ON N
981	OFFILE OF N
982	
983	- V180-

<u>984</u>	N
<u>985</u>	N
986	
<u>987</u>	Z =
<u>988</u>	N N N N N N N N N N N N N N N N N N N
989	N N N N N N N N N N N N N N N N N N N

990	6 g
<u>991</u>	N N N N N N N N N N N N N N N N N N N
992	N N N N N N N N N N N N N N N N N N N
993	
994	
<u>995</u>	
996	

997	0
998	
999	
1000	0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1001	0-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1
1002	O-N N N N N N N N N N N N N N N N N N N
1003	a





wherein the disorder is selected from the group consisting of neurological disorders, psychiatric disorders, chronic and acute pain disorders, gastrointestinal disorders, Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral selerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

- 13. (Original) The method according to claim 12, wherein the disorder is a neurological disorder
- 14. (Original) The method according to claim 12, wherein the disorder is a psychiatric disorder

 (Original) The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.

- (Original) The method according to claim 12, wherein the disorder is a gastrointestinal disorder
- 17. (Original) The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer's disease, senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down's Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.
- 18. (Withdrawn) A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.